FLCR has conducted trials across a broad range of illnesses, including anxiety disorders, ADHD, depression, bipolar disorder, schizophrenia and other mental illnesses since its founding in 2002.
It also appears that serum
FLCR may still have a role even if MALDI-TOF MS replaces electrophoresis because, in the first report, a significant number of samples that were negative by MALDI-TOF MS did have abnormal serum
FLCR, indicating that this new approach is not yet ready to be a single test screen for monoclonal gammopathy.